Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Resuscitation in Early Septic Shock Using Sodium Chloride and a Drug Combination for Patients with Septic Shock

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as septic shock. Septic shock is a serious medical condition that occurs when an infection leads to dangerously low blood pressure and other complications. The study aims to explore a new approach to treating septic shock by using a method called capillary refill time-targeted resuscitation. This method involves monitoring how quickly blood returns to the small blood vessels in the skin after pressure is applied, which can help guide treatment decisions.

Two different solutions for infusion will be used in this study. One is called Suero Fisiológico Vitulia 0.9% solution for infusion, which contains sodium chloride, a common salt used to help maintain fluid balance in the body. The other is Lactato Ringer Braun solution for infusion, which contains a mix of potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. These substances are used to help restore the balance of electrolytes, which are minerals in the body that carry an electric charge and are essential for many bodily functions.

The purpose of the study is to determine if this new treatment approach can improve outcomes for patients with septic shock, such as reducing the risk of death, shortening the time patients need vital support, and decreasing the length of hospital stay, all within 28 days. Participants in the study will receive either the new treatment approach or the usual care, and their progress will be monitored over this period. The study will help to understand if this new method can provide better results compared to the standard treatment currently used for septic shock.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient is confirmed to meet the inclusion criteria, which includes being an adult with septic shock as defined by the Sepsis-3 consensus. This involves having a suspected or confirmed infection, high levels of lactate in the blood, and a need for norepinephrine due to low blood pressure after receiving at least 1000 mL of fluids in one hour.

  2. Step 2

    Initial treatment phase

    The patient receives treatment with sodium chloride or a combination of potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. These are administered as a solution for infusion through an intravenous line. The specific solution used is either 'Suero Fisiológico Vitulia 0.9%' or 'Lactato Ringer Braun'.

  3. Step 3

    Monitoring and adjustment

    The patient's response to the treatment is closely monitored. The goal is to target the capillary refill time (CRT), which is a measure of how quickly blood returns to the capillaries after pressure is applied. Adjustments to the treatment may be made based on the patient's hemodynamic profile, which involves assessing the blood flow and circulation.

  4. Step 4

    Evaluation of outcomes

    The primary outcome of the study is a composite measure that includes all-cause mortality within 28 days, the time it takes for vital support to be no longer needed, and the length of the hospital stay, all measured within a 28-day period. Secondary outcomes focus on all-cause mortality within the same timeframe.

  5. Step 5

    Completion of the study

    The study is expected to conclude by December 19, 2025. The patient's participation will be evaluated based on the outcomes measured during the study period.

Who can join the trial?

4 criteria

  • Participants must be adults, which means they need to be **18 years or older**.
  • Participants must have **septic shock**. This is a serious condition that happens when an infection leads to very low blood pressure, even after receiving fluids.
  • Both **men and women** can participate in the study.
  • Participants should not be part of a vulnerable population, meaning they should not be in a group that needs special protection or care.

Who cannot join the trial?

3 criteria

  • Patients who are not experiencing septic shock. Septic shock is a serious condition that happens when an infection leads to dangerously low blood pressure.
  • Patients who are younger than 18 years old or older than 65 years old.
  • Patients who belong to vulnerable populations, which means groups of people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CRT-Targeted Resuscitation: This therapy involves adjusting the treatment of septic shock patients based on their capillary refill time (CRT). The goal is to improve outcomes such as survival rates, reduce the time patients need vital support, and shorten hospital stays. This approach uses clinical hemodynamic phenotyping to tailor the resuscitation process to each patient's specific needs.

What is already known about the treatment

Capillary Refill Time-Targeted Resuscitation – This approach is administered through clinical monitoring and adjustment of fluid resuscitation in patients with septic shock. It is currently being studied in clinical trials to determine its effectiveness in improving outcomes such as mortality and hospital stay duration. The main therapeutic indication is for patients experiencing septic shock, a severe and life-threatening condition. The mechanism of action involves targeting and optimizing capillary refill time, which is a measure of peripheral perfusion, to guide fluid therapy and improve hemodynamic stability. This method falls under the category of supportive care in critical care medicine.

Investigated diseases

Septic Shock – Septic shock is a severe and widespread infection that leads to dangerously low blood pressure and abnormalities in cellular metabolism. It occurs when an infection in the body triggers an extreme immune response, causing inflammation and blood clotting throughout the body. This can result in reduced blood flow to vital organs, leading to organ dysfunction. The condition progresses rapidly and requires immediate medical attention to prevent further complications. It is often associated with symptoms such as fever, chills, confusion, and difficulty breathing. The progression of septic shock can lead to multiple organ failure if not managed promptly.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519691-10-00Protocol codeANDROMEDA-SHOCK-2Estimated enrolment500 patientsSponsorPontificia Universidad Catolica de Chile

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).